TriSalus Life Sciences, Inc. — fact timeline

TriSalus Life Sciences, Inc. shareholders approved The Business Combination Proposal at the 2023-08-08 meeting.

“1. The Business Combination Proposal : For Against Abstain 7,135,003 19,016 2”

TriSalus Life Sciences, Inc. received a nasdaq deficiency notice notice regarding market value (rules 5550(b)(2)).

“June 14, 2023, MedTech Acquisition Corporation, a Delaware corporation (the “Company”), received a deficiency letter (the “Notice”) of non-compliance from the Listing Qualifications Department (the “Staff”) of the Nasdaq Stock Market (“Nasdaq”) notifying the Company that, for the preceding 30 consecutive business days, the Company’s Market Value of Listed Securities (“MVLS”) was below the $35 million minimum requirement for continued inclusion on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(b)(2) (the “MVLS Requirement”). The Notice has no immediate effect on the Company’s Na”

TriSalus Life Sciences, Inc.: Amended charter to extend business combination deadline to Sept 22, 2023, change authorized share increase vote standard, add Class B-to-Class A conversion right, and remove redemption limitation on net tangible assets (effective 2023-06-12).

“On June 12, 2023, the Company held a special meeting of stockholders (the “Meeting”). At the Meeting, the Company’s stockholders approved (1) an amendment to the Company’s Amended and Restated Certificate of Incorporation, including the amendment thereto (the “Charter”), to extend the date by which the Company must consummate its Business Combination from June 22, 2023 to September 22, 2023 (or such earlier date as determined by the Board); (2) an amendment to the Charter such that subject to the rights of the holders of any outstanding class of preferred stock, the number of authorized shares of any class of common stock or preferred stock may be increased or decreased (but not below the number of shares thereof then outstanding) by the affirmative vote of the holders of a majority of the outstanding shares of the Company’s capital stock entitled to vote thereon, irrespective of the provisions of Section 242(b)(2) of the Delaware General Corporation Law; (3) an amendment to the Charte”

TriSalus Life Sciences, Inc. shareholders approved Redemption Limitation Amendment Proposal – a proposal to amend the Company’s amended and restated certificate of incorporation to eliminate the limitation that the Company may not redeem public shares to the extent that such redemption would result in the Company having net tangible assets of less t.

“Redemption Limitation Amendment Proposal – a proposal to amend the Company’s amended and restated certificate of incorporation to eliminate the limitation that the Company may not redeem public shares to the extent that such redemption would result in the Company having net tangible assets of less than $5,000,001 in order to allow the Company to redeem public shares irrespective of whether such redemption would exceed the redemption limitation. The following is a tabulation of the votes with respect to this proposal, which was approved by the Company’s stockholders: FOR AGAINST ABSTAIN 7,496,690 322 310”

TriSalus Life Sciences, Inc. shareholders approved Founder Share Amendment Proposal – a proposal to amend the Company’s amended and restated certificate of incorporation to provide for the right of the holder of the Founder Shares to convert into Class A common stock, par value $0.0001 per share, on a one-for-one basis at any time prior to the closi.

“Founder Share Amendment Proposal – a proposal to amend the Company’s amended and restated certificate of incorporation to provide for the right of the holder of the Founder Shares to convert into Class A common stock, par value $0.0001 per share, on a one-for-one basis at any time prior to the closing of a Business Combination at the option of the holder of the Founder Shares. The following is a tabulation of the votes with respect to this proposal, which was approved by the Company’s stockholders: FOR AGAINST ABSTAIN 7,496,750 572 0”

TriSalus Life Sciences, Inc. shareholders approved Section 242(b)(2) Amendment Proposal – a proposal to amend the Company’s amended and restated certificate of incorporation such that subject to the rights of the holders of any outstanding class of preferred stock, the number of authorized shares of any class of common stock or preferred stock may b.

“Section 242(b)(2) Amendment Proposal – a proposal to amend the Company’s amended and restated certificate of incorporation such that subject to the rights of the holders of any outstanding class of preferred stock, the number of authorized shares of any class of common stock or preferred stock may be increased or decreased (but not below the number of shares thereof then outstanding) by the affirmative vote of the holders of a majority of the outstanding shares of the Company’s capital stock entitled to vote thereon, irrespective of the provisions of Section 242(b)(2) of the Delaware General Corporation Law. The following is a tabulation of the votes with respect to this proposal, which was approved by the Company’s stockholders: FOR AGAINST ABSTAIN common stock 7,496,754 568 0 Class A common stock 1,246,754 568 0 Class B common stock 6,250,000 0 0”

TriSalus Life Sciences, Inc. shareholders approved Extension Amendment Proposal – a proposal to amend the Company’s amended and restated certificate of incorporation to extend the date by which the Company has to consummate a Business Combination from June 22, 2023 to September 22, 2023 (or such earlier date as determined by the Board). at the 2023-06-22 meeting.

“The Extension Amendment Proposal – a proposal to amend the Company’s amended and restated certificate of incorporation to extend the date by which the Company has to consummate a Business Combination from June 22, 2023 to September 22, 2023 (or such earlier date as determined by the Board). The following is a tabulation of the votes with respect to this proposal, which was approved by the Company’s stockholders: FOR AGAINST ABSTAIN 6,333,932 1,163,390 0”

TriSalus Life Sciences, Inc. incurred loan of up to $137,375.28 with MedTech Acquisition Sponsor LLC at no interest maturing upon the consummation of an initial business combination.

“ote”) in the aggregate principal amount of up to $137,375.28 to the Company’s sponsor, MedTech Acquisition Sponsor LLC (the “Sponsor”) pursuant to which the Sponsor agreed to loan to the Company up to $137,375.28 to deposit into the Company’s”

TriSalus Life Sciences, Inc. entered into Subscription Agreements with certain investors valued at $17,855,020 (effective 2023-06-07).

“On June 7, 2023, the Company and certain investors (collectively, the “ Subscribers ”) entered into subscription agreements (the “ Subscription Agreements ”), pursuant to, and subject to the conditions of which, the Subscribers have collectively subscribed for and agreed to purchase 1,785,502 shares of a to-be-authorized class of preferred stock, par value $0.0001 per share that will be designated as Series A Convertible Preferred Stock (the “ Series A Convertible Preferred Stock ”), at a purchase price of $10.00 per share, resulting in an aggregate purchase price of $17,855,020.”

TriSalus Life Sciences, Inc. amended First Amendment to the Agreement and Plan of Merger (effective 2023-04-04).

“y that certain First Amendment to the Agreement and Plan of Merger, dated April 4, 2023 and that certain Second Amendment to the Agreement”

TriSalus Life Sciences, Inc. entered into Agreement and Plan of Merger with MTAC Merger Sub, Inc. and TriSalus Life Sciences, Inc. (effective 2022-11-11).

“On November 11, 2022, MedTech Acquisition Corporation, a Delaware corporation (the “ Company ”), entered into an Agreement and Plan of Merger, as amended by that certain First Amendment to the Agreement and Plan of Merger, dated April 4, 2023 and that certain Second Amendment to the Agreement and Plan of Merger, dated May 13, 2023 (as amended, the “ Merger Agreement ”), with MTAC Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of the Company (“ Merger Sub ”), and TriSalus Life Sciences, Inc., a Delaware corporation (“ TriSalus ”)”

TriSalus Life Sciences, Inc. amended Amendment to Agreement and Plan of Merger with TriSalus Life Sciences, Inc. valued at Amendment to provide for assumption by MTAC of TriSalus' restricted stock unit awards outstanding pr (effective 2023-04-04).

“On April 4, 2023, MTAC, Merger Sub, and TriSalus amended the Merger Agreement (the “ Amendment ”) to, among other matters, provide for the assumption by MTAC of any restricted stock unit awards under TriSalus’ existing equity plan that are outstanding as of immediately prior to the closing of the Business Combination, which will be converted into restricted stock unit awards covering shares of Common Stock.”

TriSalus Life Sciences, Inc. entered into Agreement and Plan of Merger with TriSalus Life Sciences, Inc. valued at Merger of Merger Sub into TriSalus, TriSalus surviving as wholly owned subsidiary of MTAC, TriSalus (effective 2022-11-11).

“On November 11, 2022, MedTech Acquisition Corporation, a Delaware corporation (“ MTAC ”), entered into an Agreement and Plan of Merger (the “ Merger Agreement ”) with MTAC Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of MTAC (“ Merger Sub ”), and TriSalus Life Sciences, Inc., a Delaware corporation (“ TriSalus ”), pursuant to which, subject to the satisfaction or waiver of certain conditions set forth therein, Merger Sub will merge with and into TriSalus (the “ Merger ”), with TriSalus surviving the Merger as a wholly owned subsidiary of MTAC, and with TriSalus’ equity holders receiving shares of MTAC common stock, par value $0.0001 per share (the “ Common Stock ” and the transactions contemplated by the Merger Agreement and the related ancillary agreements, the “ Business Combination ”).”

TriSalus Life Sciences, Inc. entered into Agreement and Plan of Merger with MedTech Acquisition Corporation valued at Merger with TriSalus surviving as wholly owned subsidiary; TriSalus equity holders receive MTAC comm (effective 2022-11-11).

“On November 11, 2022, MedTech Acquisition Corporation, a Delaware corporation (“ MTAC ”), entered into an Agreement and Plan of Merger (the “ Merger Agreement ”) with MTAC Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of MTAC (“ Merger Sub ”), and TriSalus Life Sciences, Inc., a Delaware corporation (“ TriSalus ”), pursuant to which, subject to the satisfaction or waiver of certain conditions set forth therein, Merger Sub will merge with and into TriSalus (the “ Merger ”), with TriSalus surviving the Merger as a wholly owned subsidiary of MTAC, and with TriSalus’ equity holders receiving shares of MTAC common stock”

TriSalus Life Sciences, Inc.: Amended certificate of incorporation to extend business combination deadline from December 22, 2022 to June 22, 2023 (effective 2022-12-12).

“On December 12, 2022, the Company held a special meeting in lieu of the 2022 annual meeting of stockholders (the “Meeting”). At the Meeting, the Company’s stockholders approved an amendment to the Company’s Amended and Restated Certificate of Incorporation (the “Extension Amendment”) to extend the date by which the Company must consummate its initial business combination from December 22, 2022 to June 22, 2023 (or such earlier date as determined by the Board). The Company filed the Extension Amendment with the Secretary of State of the State of Delaware on December 12, 2022.”

TriSalus Life Sciences, Inc. shareholders approved Director Election Proposal - to re-elect each of Karim Karti, Martin Roche, MD, Thierry Thaure and Manuel Aguero as Class I directors of the Board, to serve until the 2024 annual meeting of the Company or until their successors are appointed and qualified..

“(2) The Director Election Proposal — to re-elect each of Karim Karti, Martin Roche, MD, Thierry Thaure and Manuel Aguero as Class I directors of the Board, to serve until the 2024 annual meeting of the Company or until their successors are appointed and qualified. The following is a tabulation of the votes with respect to the election of directors, each of whom was elected by the Company’s stockholders: Name FOR ABSTAIN Karim Karti 19,508,998 4,429,515 Martin Roche, MD 20,704,879 3,233,634 Thierry Thaure 20,704,623 3,233,890 Manuel Aguero 20,704,875 3,233,638”

TriSalus Life Sciences, Inc. shareholders approved Extension Amendment Proposal - to amend the Company's amended and restated certificate of incorporation to extend the date by which the Company has to consummate a business combination from December 22, 2022 to June 22, 2023 (or such earlier date as determined by the Board). at the 2022-12-22 meeting.

“(1) The Extension Amendment Proposal — a proposal to amend the Company’s amended and restated certificate of incorporation to extend the date by which the Company has to consummate a business combination from December 22, 2022 to June 22, 2023 (or such earlier date as determined by the Board). The following is a tabulation of the votes with respect to this proposal, which was approved by the Company’s stockholders: FOR AGAINST ABSTAIN 20,943,728 2,962,183 32,602”

TriSalus Life Sciences, Inc. incurred loan of up to $1,000,000 with MedTech Acquisition Sponsor LLC maturing the principal amount will not be payable if the Company fails to complete its initial business combination within the required time period as set forth in its a.

“on December 16, 2022, the Company issued an unsecured promissory note in the principal amount of up to $1,000,000 (the “Working Capital Note”) to the Sponsor for working capital purposes, , which may be drawn down from time to time upon request by the Company.”

TriSalus Life Sciences, Inc. incurred loan of up to $468,821.28 with MedTech Acquisition Sponsor LLC maturing upon the date of the consummation of an initial business combination.

“On December 16, 2022, the Company issued a promissory note (the “Extension Note”) in the aggregate principal amount of up to $468,821.28 to the Company’s sponsor, MedTech Acquisition Sponsor LLC (the “Sponsor”) pursuant to which the Sponsor agreed to loan to the Company up to $468,821.28 (the “Extension Funds”) to deposit into the Company’s trust account (the “Trust Account”) for the shares of Class A common stock of the Company (the “Public Shares”) that were not redeemed in connection with the extension of the Company’s termination date from December 22, 2022 to June 22, 2023 or such earlier date as determined by the board of directors of the Company (the “Board”).”

TriSalus Life Sciences, Inc. entered into Working Capital Note with MedTech Acquisition Sponsor LLC valued at up to $1,000,000 (effective 2022-12-16).

“on December 16, 2022, the Company issued an unsecured promissory note in the principal amount of up to $1,000,000 (the “Working Capital Note”) to the Sponsor for working capital purposes”

TriSalus Life Sciences, Inc. entered into Extension Note with MedTech Acquisition Sponsor LLC valued at $468,821.28 (effective 2022-12-16).

“On December 16, 2022, the Company issued a promissory note (the “Extension Note”) in the aggregate principal amount of up to $468,821.28 to the Company’s sponsor, MedTech Acquisition Sponsor LLC (the “Sponsor”) pursuant to which the Sponsor agreed to loan to the Company up to $468,821.28”

TriSalus Life Sciences, Inc. shareholders approved The Adjournment Proposal at the 2022-12-07 meeting.

“The sole proposal that was presented at the Special Meeting was the “The Adjournment Proposal”, which is a proposal allowing the MedTech board of directors to adjourn the Special Meeting to a later date or dates, if necessary or appropriate, to provide more time to seek approval of the Extension Amendment. The MedTech stockholders approved the Adjournment Proposal. The voting results were as follows: FOR AGAINST ABSTAIN 18,357,148 4,839,932 56,835”

TriSalus Life Sciences, Inc. amended loan of $544,000 and $400,000 with MedTech Acquisition Sponsor LLC.

“disclosed, on December 30, 2021 and January 28, 2022, MedTech Acquisition Corporation (the “Company”) issued an unsecured promissory note in the principal amount of $544,000 and $400,000, respectively, to the Company’s sponsor, MedTech Acquisition Sponsor LLC (the “Sponsor”), for working capital purposes. On December 2, 2022, the Company amended both”

TriSalus Life Sciences, Inc. amended a notes offering with MedTech Acquisition Sponsor LLC (effective 2022-12-02).

“On December 2, 2022, the Company amended both promissory notes to clarify that the principal of the notes will not be payable if the Company fails to complete its initial business combination on or before the 24 month anniversary of its initial public offering or such extended date as provided in the Company's amended and restated certificate of incorporation, as amended from time to time.”

TriSalus Life Sciences, Inc. entered into Agreement and Plan of Merger with MedTech Acquisition Corporation and MTAC Merger Sub, Inc. valued at $220,000,000 (effective 2022-11-11).

“On November 11, 2022, MedTech Acquisition Corporation, a Delaware corporation (" MTAC "), entered into an Agreement and Plan of Merger (the " Merger Agreement ") with MTAC Merger Sub, Inc., a Delaware corporation and direct, wholly owned subsidiary of MTAC (" Merger Sub "), and TriSalus Life Sciences, Inc., a Delaware corporation (" TriSalus ")”

Ivan Delevic resigned as Director at TriSalus Life Sciences, Inc..

“On March 4, 2022, Ivan Delevic notified MedTech Acquisition Corporation (“MedTech” or the “Company”) that he was resigning as a member of the Company’s Board of Directors and all other positions with the Company effective immediately.”

Maurice R. Ferré resigned as Director at TriSalus Life Sciences, Inc..

“On February 19 2022, Maurice R. Ferré, MD notified MedTech Acquisition Corporation (“MedTech” or the “Company”) that he was resigning as a member of the Company’s Board of Directors and all other positions with the Company effective immediately.”